Deepak Bhatt, MD, MPH, MBA, discusses how new evidence, prevention definitions, and imaging advances are reshaping how PCSK9 ...

ELEO will provide experimental resources and screening platforms to test and refine molecules produced via computational ...

The recent approval of enlicitide was seen as a boon for some clinical scenarios, although real-world impact remains to be ...

Over the past several days, two major developments have emerged in the world of cholesterol-lowering therapies—specifically concerning the heavy-hitters known as PCSK9 inhibitors. In this letter, I’d ...

The US Food and Drug Administration has approved Merck & Co.’s cyclic peptide enlicitide decanoate for the reduction of ...

The US Food and Drug Administration has approved enlicitide (Lipfendra) as the first oral PCSK9 inhibitor for reducing LDL ...

Add Yahoo as a preferred source to see more of our stories on Google. This year at the American Diabetes Association (ADA) Scientific Sessions, new Phase III data were presented evaluating the safety ...

NEW ORLEANS—Adding the PCSK9 inhibitor evolocumab (Repatha; Amgen) to statin therapy significantly cuts the risk of major cardiovascular events when compared with statins alone in high-risk patients ...

Please provide your email address to receive an email when new articles are posted on . PCSK9 inhibitor prescriptions are rejected by insurers at a higher rate vs. other guideline-indicated ...

Please provide your email address to receive an email when new articles are posted on . PCSK9 inhibitors lower cholesterol and risk for heart disease, but barriers to access exist. A ...

With enlicitide, large LDL reductions possible without a needle ...